The more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time, explained James Hamrick, MD, senior medical director at Flatiron Health.
The more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time, explained James Hamrick, MD, senior medical director at Flatiron Health.
Transcript
When approaching patient engagement, what approach does Flatiron take to bring the most value to patients?
So, when Flatiron thinks about how we’re going to bring value to patients, in terms of patient engagement, the first thing is we firmly believe, and I think we share this belief with a lot of people in oncology, that more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time.
The things we think about are, first of all, you really need to think of patients as a very heterogenous group of people. We actually invest a fair amount in doing user research with patients where we actually speak to patients themselves in a formal, intentional way so we can begin to understand what are the different things that matter uniformly across the different groups of patients, because you really have to ask them. You get into trouble when you start assuming, “Because I’m a doctor I know,” or even “Because I’ve been in the patient’s shoes I know,” because it’s a very heterogenous group. We think about how can we get access to patients and start to understand what really does drive value.
I think the second thing that we think about is, you’ve got to meet the patients where they are. We’re a technology company, and there are a lot of people out there hypothesizing that technology is the solution to really bring value to patients in clinical care. Not everyone is on an equal level in terms of how comfortable they are with technology and how much they want to use technology to interface with their practices. So, you see some patients that are very comfortable with software portals and downloading apps; you see others that really don’t want to do that or that’s not part of how they operate. And so, we try to design things that meet patients where they are so they can be useful.
Also, we’re very aware at Flatiron of not creating products and features that worsen disparities in healthcare. We want to build products that enable the very human elements of practices and doctors connecting with patients to make patients have a better care experience, and we want to use technology as tools to help facilitate that.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More